Deciphera Pharmaceuticals is a leading biopharmaceutical company specializing in the development of targeted therapies for the treatment of cancer. The company has established its international headquarters in Zug in 2021, utilizing the Greater Zurich Area’s strong biotech ecosystem to oversee its worldwide activities.
Deciphera Pharmaceuticals has located its international headquarters in Zug, serving as the central hub for its operations across all countries outside the United States. In Zug, around 20 dedicated employees handle a range of essential functions including Commercial, Medical, Supply, Finance, Legal, Market Access, General Management, and Partner Markets.
The choice of Zug for their headquarters is deeply rooted in its exceptional pharma and biotech talent pool, excellent infrastructure, and ease of doing business, exemplified by supportive authorities and attractive tax structures. These advantages have historically benefited US pharma/biotech companies in establishing successful European operations. Deciphera’s success in Zug showcases the transformative impact of a well-assembled team, thriving in an area known for its prowess in fostering biotech innovations.
Deciphera Pharmaceuticals is a member of ONO Pharma since June 2024.
Biotech in the Greater Zurich Area
Biotech in the Greater Zurich Area
The Greater Zurich Area is one of the leading locations for biotechnology and pharmaceutical companies in Europe. The region is home to the innovative companies in the world, from Biogen and Johnson & Johnson to Roche and Amgen, and attracts capital and researchers from all over the world.
